EBV RNA Vaccines With Lipid Nanoparticles Against Weak Vaccine Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines do not effectively prevent Epstein-Barr virus (EBV) infection or disease, and there is no vaccine to prevent primary infection or disease caused by EBV, which affects a significant portion of the population, leading to symptoms like infectious mononucleosis and potential reactivation in individuals with weakened immune systems.
Innovation Solution
Development of Epstein-Barr virus (EBV) ribonucleic acid (RNA) vaccines that induce potent neutralizing antibodies and robust T cell responses, using a lipid nanoparticle delivery system to administer EBV antigens such as gp350, gH, gL, gB, LMP1, LMP2, EBNA1, and EBNA3, enhancing immune response efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines (live attenuated, inactivated, or protein subunit) are used, then they have been developed and administered, but they fail to induce sufficient neutralizing antibody titers and T cell responses to prevent EBV infection
Solution Approach 1:
The patent changes the fundamental parameter of vaccine formulation from conventional approaches to RNA-based vaccines encoding EBV antigens. This parameter change enables the induction of high neutralizing antibody titers (≥100 NT50) and robust T cell responses, directly resolving the contradiction between vaccine efficacy and immune response strength that plagued conventional vaccines
Solution Approach 2:
The patent employs composite material strategies by formulating RNA vaccines with lipid nanoparticles and adjuvants. This composite approach enhances both the delivery efficiency of the RNA and the immunogenicity of the encoded EBV antigens, achieving superior immune responses compared to conventional single-component vaccines
2Quantity of substance
If higher doses of conventional vaccines are administered, then more antigen is delivered, but the immune response remains insufficient and neutralizing antibody titers do not reach protective levels
Solution Approach 1:
The patent changes the form of antigen delivery from protein-based to RNA-based encoding, which fundamentally alters how the antigen is presented to the immune system. This parameter change allows for effective immune responses at lower doses, as the RNA is translated in situ within host cells, producing native-like antigens that elicit stronger and more durable immunity
Solution Approach 2:
The patent introduces RNA as an intermediary that carries the genetic information for EBV antigens into host cells. This intermediary approach allows the host's own cellular machinery to produce the antigens, resulting in more authentic antigen presentation and stronger immune activation compared to direct protein administration
3Reliability
If multiple doses of vaccine are administered, then immune response is boosted, but the number of doses required increases treatment complexity and time
Solution Approach 1:
The patent changes the immunogenicity parameter through RNA formulation, which inherently provides both humoral (antibody) and cellular (T cell) immune responses in a single administration. This parameter change reduces the need for multiple boosting doses, compressing the vaccination timeline while maintaining durable protective immunity
Solution Approach 2:
The patent achieves multi-functionality by designing RNA vaccines that simultaneously stimulate multiple arms of the immune system (B cells, CD4+ T cells, and CD8+ T cells) through a single vaccine formulation and administration, eliminating the need for separate prime-boost regimens required by conventional vaccines
4Ease of manufacture
If vaccine formulations are simplified, then manufacturing is easier, but efficacy against EBV is insufficient
Solution Approach 1:
The patent changes the manufacturing approach from complex multi-component protein formulations to RNA synthesis, which can be produced through in vitro transcription. This parameter change simplifies the manufacturing process while simultaneously improving efficacy, as the RNA can be rapidly synthesized and formulated with standard lipid nanoparticle technologies
Data Source
AI summary
The disclosure relates to EBV ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.